← ANALYST RATINGS · TIPRANKS
Rhythm Pharmaceuticals (RYTM): analyst forecast and price target
Analyst consensus
Strong Buy14 Buy1 Hold0 Sell
Ratings of 15 analysts in the last 3 months12-month forecast
Based on 15 price targets given in the last 3 months, the average target is $146, the highest $206, the lowest $120. The average is +69.9% from the last price of $86.17.
Analyst ratings 25
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $89.00 → $88.00−1.1% | Hold | +2.1% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| Sharon Zackfia★★★★★★★★★★#4054 · hits 44% · avg +3.0% | William Blair | $206 | Buy | +139.1% | Initiated | 15.10.26on TipRanks Oct 16 05:55 | +1.2%next day −0.9% | ↗ |
| Priyanka Grover★★★★★★★★★★#12059 · hits 12% · avg −46.0% | J.P. Morgan | $146 → $145−0.7% | Buy | +68.3% | Assigned | 15.10.26on TipRanks 07:50 | +1.2%next day −0.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $99.00 → $94.00−5.1% | Hold | +9.1% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $97.00 → $92.00−5.2% | Hold | +6.8% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $94.00 → $89.00−5.3% | Hold | +3.3% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $92.00 → $87.00−5.4% | Hold | +1.0% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $96.00 → $91.00−5.2% | Hold | +5.6% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $93.00 → $89.00−4.3% | Hold | +3.3% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $143 | Buy | +66.0% | Reiterated | 14.10.26on TipRanks Oct 15 06:10 | +1.2%next day +1.2% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $105 → $130+23.8% | Buy | +50.9% | Reiterated | 12.10.26on TipRanks 06:30 | −1.0%next day −3.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $96.00 → $99.00+3.1% | Hold | +14.9% | Reiterated | 11.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $94.00 → $97.00+3.2% | Hold | +12.6% | Reiterated | 11.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $91.00 → $94.00+3.3% | Hold | +9.1% | Reiterated | 11.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $89.00 → $92.00+3.4% | Hold | +6.8% | Reiterated | 11.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $93.00 → $96.00+3.2% | Hold | +11.4% | Reiterated | 11.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $91.00 → $93.00+2.2% | Hold | +7.9% | Reiterated | 11.10.26on TipRanks 00:05 | — | |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | — | Buy | — | Reiterated | 09.10.26on TipRanks 06:11 | +0.7%next day −1.0% · 5 days −3.1% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $101 → $96.00−5.0% | Hold | +11.4% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $98.00 → $94.00−4.1% | Hold | +9.1% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $95.00 → $91.00−4.2% | Hold | +5.6% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $93.00 → $89.00−4.3% | Hold | +3.3% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $98.00 → $93.00−5.1% | Hold | +7.9% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $95.00 → $91.00−4.2% | Hold | +5.6% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| Lisa Walter★★★★★★★★★★#5591 · hits 50% · avg +3.0% | RBC Capital | $155 → $159+2.6% | Buy | +84.5% | Reiterated | 08.10.26on TipRanks 08:10 | +1.8%next day +0.7% · 5 days −1.6% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $99.00 → $98.00−1.0% | Hold | +13.7% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $96.00 → $95.00−1.0% | Hold | +10.2% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $94.00 → $93.00−1.1% | Hold | +7.9% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $102 → $101−1.0% | Hold | +17.2% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $99.00 → $98.00−1.0% | Hold | +13.7% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $96.00 → $95.00−1.0% | Hold | +10.2% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $104 → $102−1.9% | Hold | +18.4% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $102 → $99.00−2.9% | Hold | +14.9% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $99.00 → $96.00−3.0% | Hold | +11.4% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $97.00 → $94.00−3.1% | Hold | +9.1% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $101 → $99.00−2.0% | Hold | +14.9% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $98.00 → $96.00−2.0% | Hold | +11.4% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $108 → $104−3.7% | Hold | +20.7% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $105 → $102−2.9% | Hold | +18.4% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $102 → $99.00−2.9% | Hold | +14.9% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $100 → $97.00−3.0% | Hold | +12.6% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $104 → $101−2.9% | Hold | +17.2% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $101 → $98.00−3.0% | Hold | +13.7% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $108 | Hold | +25.3% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $105 | Hold | +21.9% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $102 | Hold | +18.4% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $100 | Hold | +16.0% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $104 | Hold | +20.7% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $101 | Hold | +17.2% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | — | Buy | — | Initiated | 17.09.26on TipRanks 07:25 | −0.1%next day −1.5% · 5 days −1.6% | ↗ |
| Priyanka Grover★★★★★★★★★★#12059 · hits 12% · avg −46.0% | J.P. Morgan | — | Buy | — | Reiterated | 15.09.26on TipRanks Sep 16 04:00 | −5.1%next day +1.7% · 5 days +0.2% | ↗ |
| Lisa Walter★★★★★★★★★★#5591 · hits 50% · avg +3.0% | RBC Capital | $155 | Buy | +79.9% | Reiterated | 14.09.26on TipRanks 21:45 | −5.1%next day +1.7% · 5 days +0.2% | ↗ |
| Name not given | — | $133 | Buy | +54.3% | Initiated | 14.09.26on TipRanks 12:15 | −1.7%next day −5.1% · 5 days −5.4% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $120 | Hold | +39.3% | Initiated | 27.08.26on TipRanks Aug 28 04:40 | −0.1%next day −4.5% · 5 days −7.1% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $150 | Buy | +74.1% | Reiterated | 24.08.26on TipRanks Aug 25 07:13 | +1.6%next day +1.4% · 5 days −5.2% | ↗ |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | $143 | Buy | +66.0% | Reiterated | 24.08.26on TipRanks Aug 25 06:50 | +1.6%next day +1.4% · 5 days −5.2% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $151 → $154+2.0% | Buy | +78.7% | Reiterated | 05.08.26on TipRanks 07:25 | +4.9%next day +1.4% · 5 days +5.9% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $142 → $143+0.7% | Buy | +66.0% | Reiterated | 05.08.26on TipRanks 06:40 | +4.9%next day +1.4% · 5 days +5.9% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $155 → $160+3.2% | Buy | +85.7% | Reiterated | 05.08.26on TipRanks 05:55 | +4.9%next day +1.4% · 5 days +5.9% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $149 | Buy | +72.9% | Reiterated | 04.08.26on TipRanks Aug 5 04:31 | +1.1%next day +4.9% · 5 days +6.8% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | $130 | Buy | +50.9% | Assigned | 04.08.26on TipRanks Aug 5 02:50 | +1.1%next day +4.9% · 5 days +6.8% | ↗ |
| Joseph Stringer★★★★★★★★★★#293 · hits 48% · avg +24.7% | Needham | $130 | Buy | +50.9% | Reiterated | 04.08.26on TipRanks 12:51 | +1.1%next day +4.9% · 5 days +6.8% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $155 | Buy | +79.9% | Assigned | 16.07.26on TipRanks 06:55 | −2.7%next day +1.5% · 5 days −1.6% | ↗ |
| Dennis Ding★★★★★★★★★★#2230 · hits 58% · avg +12.3% | Jefferies | $125 | Buy | +45.1% | Reiterated | 15.06.26on TipRanks 10:15 | −0.3%next day +0.6% · 5 days +20.9% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $133 | Buy | +54.3% | Reiterated | 15.06.26on TipRanks 07:10 | −0.3%next day +0.6% · 5 days +20.9% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $105 | Buy | +21.9% | Reiterated | 15.06.26on TipRanks 06:15 | −0.3%next day +0.6% · 5 days +20.9% | ↗ |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $158 → $159+0.6% | Buy | +84.5% | Reiterated | 14.06.26on TipRanks Jun 15 07:50 | −0.3%next day +0.6% · 5 days +20.9% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | — | Hold | — | Downgrade | 04.11.25on TipRanks Nov 5 04:55 | −6.5%next day −5.6% · 5 days −6.0% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Rhythm Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $144 at a price of $95.22 (+50.7%); now: $146 at $86.17 (+69.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 18 | 10 | 8 | 6 | 1 | 5 |
| Buy | 24 | 19 | 22 | 22 | 20 | 17 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.71 (from $-0.85 to $-0.54). Last quarter: $-0.73.
Sales
Next quarter’s sales estimate — $85M (from $78M to $98M). Last quarter: $71M.
Best top-analyst consensus in the sector · Healthcare
About Rhythm Pharmaceuticals
- CEO: David Meeker
- Employees: 414
- 222 Berkeley Street, Boston, MA, 02116, US
- www.rhythmtx.com
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Data from the stock’s TipRanks forecast page, read 37 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗